Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Analysts have a consensus “Hold” rating on Amgen: Among 31 brokerages, 13 rate the stock a buy, 14 recommend holding, and three rate it a sell. The average 12-month price target is $380.43, below the reported $432.42 share price.
• Recent financial results exceeded expectations. Amgen reported quarterly earnings of $6.29 per share and revenue of $10.05 billion, surpassing estimates, while revenue rose 9.5% year over year. The company also maintained 2026 EPS guidance of $22.30–$23.50.
• Pipeline developments provide mixed signals. Positive Phase 3 results could expand Tezspire into eosinophilic esophagitis, but Amgen ended its Crohn’s disease research partnership with TScan Therapeutics; insiders have also sold more than $2.5 million of stock over the past three months.

Shares of Amgen Inc. (NASDAQ:AMGN - Get Free Report) have been assigned an average recommendation of "Hold" from the thirty-one brokerages that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $380.4286.

AMGN has been the subject of several recent research reports. Robert W. Baird boosted their target price on shares of Amgen from $215.00 to $230.00 and gave the stock an "underperform" rating in a research report on Wednesday, August 5th. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a report on Friday, June 5th. Truist Financial upped their price objective on shares of Amgen from $340.00 to $362.00 and gave the stock a "hold" rating in a report on Wednesday, August 5th. Canaccord Genuity Group increased their target price on shares of Amgen from $366.00 to $384.00 and gave the stock a "hold" rating in a research report on Wednesday, August 5th. Finally, TD Cowen increased their target price on shares of Amgen from $420.00 to $452.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 2,000 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares of the company's stock, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amgen

A number of institutional investors have recently modified their holdings of the company. Adell Harriman & Carpenter Inc. boosted its stake in Amgen by 7.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company's stock valued at $7,204,000 after purchasing an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in Amgen in the 4th quarter valued at approximately $22,441,000. Sigma Planning Corp increased its position in Amgen by 24.0% in the 4th quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company's stock worth $5,889,000 after buying an additional 3,488 shares during the period. National Pension Service increased its position in Amgen by 4.7% in the 4th quarter. National Pension Service now owns 1,239,549 shares of the medical research company's stock worth $405,717,000 after buying an additional 55,489 shares during the period. Finally, Integrated Advisors Network LLC lifted its holdings in shares of Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company's stock worth $6,664,000 after buying an additional 6,356 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire expands its potential market. Amgen and AstraZeneca reported that Tezspire met both co-primary and all key secondary endpoints in the Phase 3 CROSSING study for eosinophilic esophagitis (EoE). Improvements in tissue inflammation and swallowing symptoms were statistically significant, clinically meaningful and sustained through 52 weeks. EoE could become Tezspire’s third approved indication, adding a potentially significant growth opportunity beyond asthma and chronic rhinosinusitis with nasal polyps. Tezspire Phase 3 EoE Results
• Positive Sentiment: Recent financial performance remains supportive. Amgen’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue increasing year over year. Strong results and full-year guidance have helped keep the stock near its 52-week high and provide a favorable backdrop for pipeline news. Amgen Earnings and Guidance
• Neutral Sentiment: Additional pipeline updates offer limited near-term valuation impact. Amgen provided updates on a pediatric psoriasis study involving apremilast and began a Phase 1 trial of AMG 691 aimed at markets in Asia. These programs may support long-term growth, but both remain too early to materially affect current earnings expectations. Amgen Pediatric Psoriasis Study
• Negative Sentiment: Amgen ended its Crohn’s disease research partnership with TScan Therapeutics. Terminating the collaboration removes an external source of potential inflammatory bowel disease assets and may raise questions about the company’s strategy in this research area. The impact is likely limited near term because the program was still focused on target discovery. Amgen Ends Crohn’s Research Partnership

Amgen Stock Down 1.0%

Shares of Amgen stock opened at $432.42 on Friday. The firm has a market cap of $233.78 billion, a price-to-earnings ratio of 26.88, a P/E/G ratio of 3.16 and a beta of 0.41. The stock has a 50-day simple moving average of $388.64 and a 200-day simple moving average of $364.71. Amgen has a 52-week low of $269.77 and a 52-week high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm's revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts expect that Amgen will post 22.92 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen's dividend payout ratio is 62.65%.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source